Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
7.69
-0.03 (-0.39%)
At close: Aug 8, 2025, 4:00 PM
7.68
-0.01 (-0.11%)
After-hours: Aug 8, 2025, 7:04 PM EDT
Paramount Global Employees
Prothena Corporation had 163 employees as of December 31, 2024. The number of employees decreased by 10 or -5.78% compared to the previous year.
Employees
163
Change (1Y)
-10
Growth (1Y)
-5.78%
Revenue / Employee
$63,442
Profits / Employee
-$1,858,399
Market Cap
413.95M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 163 | -10 | -5.78% |
Dec 31, 2023 | 173 | 46 | 36.22% |
Dec 31, 2022 | 127 | 45 | 54.88% |
Dec 31, 2021 | 82 | 16 | 24.24% |
Dec 31, 2020 | 66 | 15 | 29.41% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PRTA News
- 4 days ago - Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 6 days ago - Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 13 days ago - Prothena to Report Second Quarter 2025 Financial Results on August 4 - Business Wire
- 7 weeks ago - Prothena Announces Corporate Restructuring - Business Wire
- 7 weeks ago - Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Business Wire
- 2 months ago - Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
- 2 months ago - Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint - Business Wire
- 3 months ago - Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - Benzinga